Investors should monitor enrollment progress in the Phase 3 EMBARQ trial and upcoming interim or topline results, which could serve as major catalysts. The retreatment data de-risk development by supporting flexible dosing, potentially improving compliance and commercial adoption.
CLDX drugs
CLDX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $30.00entry
- T+1 · 9mo ago −3.53%α −2.62% · $28.94
- T+5 · 8mo ago +2.43%α +3.64% · $30.73
- T+20 · 8mo ago −1.73%α +6.20% · $29.48
- T+60 · 6mo ago +2.83%α −6.49% · $30.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celldex Therapeutics presented positive Phase 2 open-label extension data for barzolvolimab in ColdU and SD, showing that retreatment leads to rapid and high rates of complete response, supporting the potential for intermittent, real-world treatment. The data reinforce the drug's durable efficacy and favorable safety profile, with 62% (ColdU) and 60% (SD) achieving complete response upon retreatment. A global Phase 3 trial is ongoing.
Key Facts
- Barzolvolimab retreatment achieved 62% complete response in ColdU and 60% in SD at Week 20 of the OLE, consistent with initial treatment efficacy.
- Among patients who achieved complete response initially, 82% (ColdU) and 86% (SD) achieved it again upon retreatment.
- Rapid improvement in urticaria control and symptom thresholds observed upon retreatment.
- Barzolvolimab targets mast cells via KIT receptor inhibition, a novel mechanism for chronic inducible urticarias.
- Global Phase 3 trial (EMBARQ-ColdU and SD, NCT07266402) is enrolling, initiated in late 2025.
Financial Impact
High potential commercial value; addresses an underserved market with no approved therapies beyond antihistamines. Phase 3 advancement increases probability of regulatory approval and future revenue generation.
Risk Factors
- Phase 3 trial may not replicate Phase 2 results.
- Regulatory approval not guaranteed despite promising data.
- Competition could emerge if other mast cell or biologic therapies advance in urticaria.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3246936 |
Track record
21 reports on CLDX
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 3 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 Now $28.83 −0.48% settles Feb 12
- Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 Now $28.83 −3.48% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 Now $28.83 −3.48% settles Feb 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 Now $28.83 −2.96% settles Feb 1
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 Now $28.83 −5.26% settles Jan 4
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 Now $28.83 −13.97% settles Dec 16
- Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 Now $28.83 −13.97% settles Dec 16
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 Now $28.83 −13.97% settles Dec 16
- Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 Now $28.83 +10.24% ▼ −18.62% −18.22% vs SPY
- Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 Now $28.83 −10.24% ▲ +18.62% +18.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers